Isocitrate dehydrogenase inhibitor‐driven differentiation may resemble secondary graft failure in post‐allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia

Targeted isocitrate dehydrogenase (IDH) inhibitor (IDHi) therapy is frequently used in patients with IDH -mutated acute myeloid leukaemia (AML). Here, we describe two patients with IDH -mutated AML who relapsed after allogeneic haematopoietic cell transplant (HCT) and were treated with IDHi therapy. Both patients showed evidence of differentiation, a known effect of IDHi therapy, which mani-fested as a significant but transient drop in donor chimaerism.

[1]  S. Choe,et al.  A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. , 2021, Blood advances.

[2]  G. Lip,et al.  Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials , 2021, medRxiv.

[3]  Matthew J. Frigault,et al.  A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation , 2020, Blood.

[4]  D. Jiménez,et al.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.

[5]  F. de Cobelli,et al.  Spontaneous Major Hemorrhage in COVID-19 Patients: Another Brick in the Wall of SARS-CoV-2–Associated Coagulation Disorders? , 2020, Journal of Vascular and Interventional Radiology.

[6]  Y. Kanthi,et al.  COVID–19-associated coagulopathy: An exploration of mechanisms , 2020, Vascular medicine.

[7]  S. Lane,et al.  Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor? , 2020, American journal of respiratory and critical care medicine.

[8]  R. Jayani,et al.  The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia , 2020, American journal of hematology.

[9]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[10]  D. King,et al.  Spontaneous Retroperitoneal and Rectus Sheath Hemorrhage—Management, Risk Factors and Outcomes , 2019, World Journal of Surgery.

[11]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[12]  P. Vyas,et al.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.

[13]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[14]  C. Dinardo,et al.  Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. , 2016, Clinical lymphoma, myeloma & leukemia.

[15]  Daniel Cabrera,et al.  Spontaneous retroperitoneal hematoma: etiology, characteristics, management, and outcome. , 2012, The Journal of emergency medicine.

[16]  A. Segado Soriano,et al.  [Spontaneous retroperitoneal hemorrhage]. , 1995, Anales de medicina interna.

[17]  M. A. Tomlinson,et al.  Retroperitoneal haematoma. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.